A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.
A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.
复制标题
一项 II 期研究，旨在评估对超过两剂纳武单抗伊匹单抗联合（组合）免疫疗法的需求。
DOI：
10.1200/jco.2020.38.15_suppl.10003
复制
发表时间：
2020
影响因子：
45.3
通讯作者：
P. Chapman
中科院分区：
文献类型：
--
作者：
M. Postow;D. Goldman;A. Shoushtari;A. B. Warner;M. Callahan;P. Momtaz;E. Naito;O. Eton;S. Nair;J. Wolchok;K. Panageas;P. Chapman
10003背景：对于不可切除的III/IV期黑色素瘤患者，标准治疗方案是给予纳武利尤单抗（nivo）+伊匹木单抗（ipi）联合免疫治疗4个剂量。是否需要4个剂量……
10003Background: Standard of care nivolumab (nivo) + ipilimumab (ipi) combo immunotherapy is given for 4 doses in patients (pts) with unresectable stage III/IV melanoma. Whether 4 doses are needed ...